Neutralizing antibodies of botulinum neurotoxin serotype a screened from a fully synthetic human antibody phage display library

Journal of Biomolecular Screening

Volumn 14, Issue 8, 2009, Pages 991-998

  Yu, Rui ^a   Wang, Shuang ^a   Yu, Yun Zhou ^a   Du, Wei Shi ^a   Yang, Fang ^a   Yu, Wei Yuan ^a   Sun, Zhi Wei ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

Botulinum neurotoxins; Fully synthetic human antibody library; Hc fragment; Neutralizing antibody; Phage display

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN A NEUTRALIZING ANTIBODY; EPITOPE; IMMUNOGLOBULIN G4 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1B6; MONOCLONAL ANTIBODY C10; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY LIBRARY; ANTIBODY SCREENING; ARTICLE; BOTULISM; CELL DEATH; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; EPITOPE MAPPING; FEMALE; GENE MAPPING; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LD 50; MOLECULAR CLONING; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RAT;

CLOSTRIDIUM BOTULINUM; MUS;

EID: 70349644972     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057109343206     Document Type: Article

References (29)

1. Arnon SS, Schechter R., Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001 ; 285: 1059-1070.
2. Amersdorfer P., Wong C., Chen S., Smith T., Deshpande S., Sheridan R., et al. Molecular characterization of murine humoral immuneresponse to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun 1997 ; 65: 3743-3752.
3. Sheets MD, Amersdorfer P., Finnern R., Sargent P., Lindquist E., Schier R., et al. Efficient construction of large non-immune phage antibody library: the production of high affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci USA 1998 ; 95: 6157-6162.
4. de Haard HJ, van Neer N., Reurs A., Hufton SE, Roovers RC, Henderikx P., et al. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Bio Chi 1999 ; 274: 18218-18230.
5. Griffiths AD, Williams SC, Hartley O., Tomlinson IM, Waterhouse P., Crosby WL, et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994 ; 13: 3245-3260.
6. Knappik A., Ge L., Honegger A., Pack P., Fischer M., Wellnhofer G., et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000 ; 296: 57-86.
7. Volkel T., Muller R., Kontermann RE Isolation of endothelial cell-specific human antibodies from a novel fully synthetic scFv library. Bioch Biophy Res Commun 2004 ; 317: 515-521.
8. Silacci M., Brack S., Schirru G., MÄrlind J., Ettorre A., Merlo A., et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 2005 ; 5: 2340-2350.
9. Lacy DB, Tepp W., Cohen AC, DasGupta BR, Stevens RC: Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 1998 ; 5: 898-902.
10. Tavallaie M., Chenal A., Gillet D., Pereira Y., Manich M., Gibert M., et al. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett 2004 ; 572: 299-306.
11. Yu YZ, Sun ZW, Wang S., Yu WY: High-level expression of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen. Sheng Wu Gong Cheng Xue Bao 2007 ; 23: 812-817.
12. Tomlinson IM, Cox JP, Gherardi E., Lesk AM, Chothia C.: The structural repertoire of the human V° domain. EMBO J 1995 ; 14: 4628-4638.
13. Williams SC, Frippiat JP, Tomlinson IM, Ignatovich O., Lefranc MP, Winter G.: Sequence and evolution of the human germline V» repertoire. J Mol Biol 1996 ; 264: 220-232.
14. Shirai H., Kidera A., Nakamura H.: Structural classification of CDR-H3 in antibodies. FEBS Lett 1996 ; 399: 1-8.
15. Oliva B., Bates PA, Querol E., Avilĩs FX, Sternberg MJ: Automated classification of antibody complementarity determining region 3 of the heavy chain(H3) loops into canonical forms and its application to protein structure prediction. J Mol Biol 1998 ; 279: 1193-1210.
16. Shone CC, Melling J.: Inhibition of calcium-dependent release of noradrenaline from PC-12 cells by botulinum type-A neurotoxin. Eur J Biochem 1992 ; 207: 1009-1016.
17. Burnett JC, Ruthel G., Stegmann CM, Panchal RG, Nguyen TL, Hermone AR, et al. Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem 2007 ; 282: 5004-5014.
18. Blommaert A., Turcaud S., Anne C., Roques BP: Small tripeptide surrogates with low nanomolar affinity as potent inhibitors of the botulinum neurotoxin B metallo-proteolytic activity. Bioorg Med Chem 2004 ; 12: 3055-3062.
19. de Paiva A., Ashton AC, Foran P., Schiavo G., Montecucco C., Dolly JO: Botulinum A like type B and tetanus toxins fulfils criteria for being a zinc-dependent protease. J Neurochem 1993 ; 61: 2338-2341.
20. Marks JD: Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord 2004 ; 19 (suppl 8). S101 - S108.
21. Mowry MC, Meagher M., Smith L., Marks J., Subramanian AP: Production and purification of a chimeric monoclonal antibody against botulinum neurotoxin serotype A. Protein Expr Purif 2004 ; 37: 399-408.
22. Mah DC, Hu WG, Pon JK, Masri SA, Fulton RE, Monette PL, et al. Recombinant anti-botulinum neurotoxin a single-chain variable fragment antibody generated using a phage display system. Hybrid Hybridomics 2003 ; 22: 277-283.
23. Pless DD, Torres ER, Reinke EK, Bavari S.: High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect Immun 2001 ; 69: 570-574.
24. Amersdorfer P., Marks JD: Phage libraries for generation of anti-botulinum scfv antibodies. Methods Mol Biol 2000 ; 145: 219-240.
25. Lee MS, Lee JC, Choi CY, Chung J.: Production and characterization of monoclonal antibody to botulinum neurotoxin type B light chain by phage display. Hybridoma (Larchmt) 2008 ; 27: 18-24.
26. Nowakowski A., Wang C., Powers DB, Amersdorfer P., Smith TJ, Montgomery VA, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 2002 ; 99: 11346-11350.
27. Amersdorfer P., Wong C., Smith T., Chen S., Deshpande S., Sheridan R., et al. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine 2002 ; 20: 1640-1648.
28. Hoogenboom HR, Winter G.: By-passing immunization: human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J Mol Biol 1992 ; 227: 381-388.
29. Montecucco C.: How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci 1986 ; 11: 315-317.